First patients for trial that investigates adaptive treatment for ovarian cancer
The Anticancer Fund and Barts Charity are co-funding the ACTOv-trial, which has enrolled its first patients in the United Kingdom. This study is investigating a new personalised treatment approach for ovarian cancer that has returned after previous chemotherapy. The aim is to prolong patients’ survival and reduce side-effects.
